NCT01623375View on ClinicalTrials.gov

A Trial Investigating the Absolute Bioavailability of Insulin Degludec in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
DiabetesHealthy
Interventions
DRUG

insulin degludec

A single dose of 0.4 U/kg body weight will be administered subcutaneously (s.c., under the skin).

DRUG

insulin degludec

A single dose of 0.04 U/kg body weight will be administered intravenously (i.v., into the vein).

Trial Locations (1)

41460

Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY